NCT00968422View on ClinicalTrials.gov

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2010

Conditions
Healthy
Interventions
DRUG

ABT-384

3 escalating doses will be administered daily for 21 days

DRUG

Matching placebo to ABT-384

Doses will be administered daily for 21 days

Trial Locations (1)

32809

Site Reference ID/Investigator# 23024, Orlando

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY